DR. MICHAEL TSUYOSHI CHEW MD, MS
Prescription History 1487912697
Internal Medicine - Gastroenterology in Portland, OR

NPI Status: Active since April 25, 2012

Contact Information

9701 SW BARNES RD STE 300
PORTLAND, OR
ZIP 97225
Phone: (503) 297-8081
Fax: (503) 292-6601

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MICHAEL TSUYOSHI CHEW MD, MS, an active Gastroenterology specialist practicing in Portland, OR. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 431 documented patient claims. Among these therapy options, the most frequently utilized medication is Gavilyte-C, which accounts for 301 claims alone.

Medication Index


Budesonide Dr

Generic Formulation: BudesonideSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 12
30-Day Fills 21.2
Days Supply 622
OR State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills32.7
Peer Average Days Supply970
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,046.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$87.23

State Avg Cost Per Claim

$179.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.

Therapeutic Applications

Budesonide is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. This medication belongs to a class of drugs known as corticosteroids. It works directly in the lungs to make breathing easier by reducing the irritation and swelling of the airways. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Dexlansoprazole Dr

Generic Formulation: DexlansoprazoleSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
OR State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply559
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,331.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$360.93

State Avg Cost Per Claim

$304.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.

Therapeutic Applications

Dexlansoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Dexlansoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). Dexlansoprazole is not recommended for use in children younger than 2 years due to an increased risk of serious side effects. Ask the doctor or pharmacist for details.

Gavilyte-C

Generic Formulation: Peg3350/Sod Sulf,bicarb,cl/KclSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 301
30-Day Fills 302.0
Days Supply 507
OR State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills43.5
Peer Average Days Supply72
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 600.0% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,373.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.50

State Avg Cost Per Claim

$18.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

PEG (polyethylene glycol) with electrolyte is used to clean out the intestines before certain bowel exam procedures such as colonoscopy or barium enema X-rays. It is a laxative that works by drawing large amounts of water into the colon. This effect results in watery bowel movements. Clearing stool from the intestines helps your doctor to better examine the intestines during your procedure.

Lialda

Generic Formulation: MesalamineSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 19
30-Day Fills 51.0
Days Supply 1,530
OR State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills90.6
Peer Average Days Supply2,717
Conservative Utilization

This provider writes prescriptions for this formulation 48.6% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,567.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$398.32

State Avg Cost Per Claim

$521.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Therapeutic Applications

This medication is used to treat a certain bowel disease (ulcerative colitis). It helps to reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain. Mesalamine belongs to a class of drugs known as aminosalicylates. It works by decreasing swelling in the colon.

Lubiprostone

Generic Formulation: LubiprostoneSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 24
30-Day Fills 38.0
Days Supply 1,110
OR State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills16.7
Peer Average Days Supply461
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.0% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,771.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$157.13

State Avg Cost Per Claim

$323.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Member of a bicyclic fatty acid class of compounds derived from PROSTAGLANDIN E1 involved in chloride channel gating.

Therapeutic Applications

This medication is used to treat certain types of constipation (chronic idiopathic constipation, irritable bowel syndrome with constipation). Chronic idiopathic constipation has an unknown cause and is not due to diet, other diseases, or drugs. Lubiprostone is also used to treat constipation caused by opioid medications in people with ongoing pain due to medical conditions other than cancer. This medication may improve symptoms such as bloating and abdominal discomfort, improve stool texture, lessen the need to strain, and decrease the feeling of not completely relieving oneself. Lubiprostone belongs to a class of drugs known as chloride channel activators. It works by increasing the amount of fluid within your intestines, making the passage of stool easier.

Mesalamine

Generic Formulation: MesalamineSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 11
30-Day Fills 25.5
Days Supply 717
OR State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills40.5
Peer Average Days Supply1,197
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.2% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,567.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$324.36

State Avg Cost Per Claim

$707.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Therapeutic Applications

This medication is used to treat a certain bowel disease (ulcerative colitis). It helps to reduce symptoms of ulcerative colitis such as diarrhea, rectal bleeding, and stomach pain. Mesalamine belongs to a class of drugs known as aminosalicylates. It works by decreasing swelling in the colon.

Pantoprazole Sodium

Generic Formulation: Pantoprazole SodiumSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 52
30-Day Fills 134.0
Days Supply 3,988
OR State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills99.4
Peer Average Days Supply2,956
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $726.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.97

State Avg Cost Per Claim

$18.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Therapeutic Applications

Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MICHAEL TSUYOSHI CHEW MD, MS provides transparency into local medical care patterns within Portland, OR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Gastroenterology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.